Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy (ULSPABIT)
Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting First Time or Switching to a New Biological Therapy; the ULSpABiT Study.
Patients with spondylarthritis (SpA) (including ankylosing spondylitis, psoriatic arthritis, arthritis as part of inflammatory bowel disease and reactive arthritis) have axial involvement (the spine) as well as peripheral inflammation in joints and entheses (where the tendons and ligaments are anchored to the bone). Patients with high disease activity of SpA may need biological treatment (anti-TNF alpha), which are very expensive medications. Thus it is necessary to have a sensitive method for assessing the response to treatment. Ultrasonography (US) is a validated and reliable method for assessing disease activity in joints and tendons, and may be used to follow the treatment response.
The present study will include patients with SpA starting on anti-TNF alpha treatment (as first biologic medication or when switching to a new biologic treatment). The study is an extension of the ongoing NORDMARD study (Norwegian longitudinal observational study of arthritic patients starting disease-modifying treatment). The patients will be examined by use of US of 38 joints and 14 entheses at baseline and after 3, 6 and 12 months.
The objectives are to explore US as a method to assess peripheral inflammatory activity for evaluation of response to medication as well as to compare the US pathology with clinical and laboratory findings.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Oslo, Norvège, 0319
- Department of Rheumatology, Diakonhjemmet Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- SpA
- Planning to start anti-TNF alpha treatment
Exclusion Criteria:
- Patients not being able to communicate in Norwegian or not being able to fill in questionnaires
- Surgery in more than 5 of the joints/entheses to be examined by US
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
SpA patients
The patients may be included when their rheumatologist has decided that the patient are going to start biological medication.
|
All medical treatment will be standardizes following good medical practice
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
To assess the sensitivity to change of US pathology in joints and entheses in SpA patients starting biological treatment.
Délai: Including patients for about 1.5 years
|
The joints will be assessed according to a US atlas by use of a semi-quantitative (0-3) scoring system and the entheses will be evaluated according to internationally accepted scoring methods.
|
Including patients for about 1.5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
1. Explore whether the US (B-mode and power Doppler) scores at baseline or after 3 months predict patients responding to biological treatment after 6 and 12 months.
Délai: 2.5 years
|
2.5 years
|
|
|
2. Explore whether the sensitivity for change is higher for US (B-mode and/or power Doppler) than for the traditional assessments for inflammatory activity.
Délai: 2.5 years
|
2.5 years
|
|
|
3. Explore potential differences of US detected pathology in joints and entheses between subgroups of spondylarthritis patients.
Délai: 2.5 years
|
2.5 years
|
|
|
4. Explore whether the different subgroups of spondylarthritis patients have different US response (B-mode synovitis and power Doppler in joints and entheses) to biological treatment.
Délai: 2.5 years
|
2.5 years
|
|
|
5. Explore the association between the US findings (BM and/or PD) and the patient's experience of pain and fatigue.
Délai: 2.5 years
|
2.5 years
|
|
|
6. Explore the associations between calprotectin and US detected inflammation in joints and/or entheses as well as traditional assessments of disease activity.
Délai: 2.5 years
|
Calprotectin, a major granulocyte protein, is assessed by use of ELISA in plasma.
Plasma samples will be frozen at all visits, and the calprotectin assessments will be performed when all patients have finished the study.
|
2.5 years
|
|
7. Explore whether baseline calprotectin or other biomarkers in blood may predict response to biological medication.
Délai: 2.5 years
|
Plasma and serum will be frozen at each visit, and the S100 proteins calprotectin as well as A12 will be assessed.
In addition, other relevant biomarkers may be analyzed after 2.5 years.
|
2.5 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Hilde B Hammer, MD, PhD, Diakonhjemmet Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Infections
- Maladies articulaires
- Maladies musculo-squelettiques
- Arthrite
- Maladies de la colonne vertébrale
- Maladies osseuses
- Maladies osseuses, infectieuses
- Spondylarthrite
- Spondylarthrite
- Effets physiologiques des médicaments
- Agents du système nerveux périphérique
- Analgésiques
- Agents du système sensoriel
- Agents anti-inflammatoires non stéroïdiens
- Analgésiques, non narcotiques
- Agents anti-inflammatoires
- Agents antirhumatismaux
- Agents immunosuppresseurs
- Facteurs immunologiques
- Agents gastro-intestinaux
- Agents dermatologiques
- Inhibiteurs du facteur de nécrose tumorale
- Étanercept
- Adalimumab
- Infliximab
- Golimumab
Autres numéros d'identification d'étude
- 011110
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .